Apr 10, 2013 9:15 am EDT SCYNEXIS and Immune Design Collaborate on Innovative Process for Vaccine Production Technology
Nov 11, 2012 4:45 pm EST SCYNEXIS’ Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
Sep 4, 2012 8:00 am EDT SCYNEXIS® Announces Exclusive Licensing Deal for the Treatment of Canine Dry Eye
Aug 20, 2012 9:18 am EDT SCYNEXIS to Present on Screening Technology Used in Anti-Malarial Research at ACS National Meeting
Mar 28, 2012 8:05 am EDT Abide Therapeutics and SCYNEXIS Collaborate in Finding Novel Anti-Viral and Anti-Parasitic Agents
Feb 16, 2012 9:52 am EST Morria Biopharmaceuticals Plc Selects SCYNEXIS to Support CMC Activities for MRX-4, a Novel Anti-Inflammatory Drug for Allergic Rhinitis
Dec 19, 2011 9:00 am EST MMV and SCYNEXIS Offer 400 Active Compounds for Neglected Disease Drug Research at No Cost
Jul 12, 2011 8:20 am EDT Innovative Vector Control Consortium Announces Discovery Project With SCYNEXIS
